250 related articles for article (PubMed ID: 16580970)
1. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.
Holenz J; Pauwels PJ; Díaz JL; Mercè R; Codony X; Buschmann H
Drug Discov Today; 2006 Apr; 11(7-8):283-99. PubMed ID: 16580970
[TBL] [Abstract][Full Text] [Related]
2. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H
Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
[TBL] [Abstract][Full Text] [Related]
3. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.
Holenz J; Mercè R; Díaz JL; Guitart X; Codony X; Dordal A; Romero G; Torrens A; Mas J; Andaluz B; Hernández S; Monroy X; Sánchez E; Hernández E; Pérez R; Cubí R; Sanfeliu O; Buschmann H
J Med Chem; 2005 Mar; 48(6):1781-95. PubMed ID: 15771424
[TBL] [Abstract][Full Text] [Related]
4. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
Geldenhuys WJ; Van der Schyf CJ
Expert Rev Neurother; 2009 Jul; 9(7):1073-85. PubMed ID: 19589055
[TBL] [Abstract][Full Text] [Related]
5. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds.
Ivachtchenko AV; Ivanenkov YA; Skorenko AV
Expert Opin Ther Pat; 2012 Oct; 22(10):1123-68. PubMed ID: 22957857
[TBL] [Abstract][Full Text] [Related]
6. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
Holmberg P; Sohn D; Leideborg R; Caldirola P; Zlatoidsky P; Hanson S; Mohell N; Rosqvist S; Nordvall G; Johansson AM; Johansson R
J Med Chem; 2004 Jul; 47(16):3927-30. PubMed ID: 15267230
[TBL] [Abstract][Full Text] [Related]
7. Identification of a series of benzoxazoles as potent 5-HT6 ligands.
Liu KG; Lo JR; Comery TA; Zhang GM; Zhang JY; Kowal DM; Smith DL; Di L; Kerns EH; Schechter LE; Robichaud AJ
Bioorg Med Chem Lett; 2009 Feb; 19(4):1115-7. PubMed ID: 19152787
[TBL] [Abstract][Full Text] [Related]
8. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.
Geldenhuys WJ; Van der Schyf CJ
Curr Top Med Chem; 2008; 8(12):1035-48. PubMed ID: 18691131
[TBL] [Abstract][Full Text] [Related]
9. 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia.
Johnson CN; Ahmed M; Miller ND
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):642-54. PubMed ID: 18729016
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 5-HT6 receptor ligands based on virtual HTS.
Tasler S; Kraus J; Wuzik A; Müller O; Aschenbrenner A; Cubero E; Pascual R; Quintana-Ruiz JR; Dordal A; Mercè R; Codony X
Bioorg Med Chem Lett; 2007 Nov; 17(22):6224-9. PubMed ID: 17892934
[TBL] [Abstract][Full Text] [Related]
11. 5-HT(7) receptor modulators: a medicinal chemistry survey of recent patent literature (2004 - 2009).
Leopoldo M; Lacivita E; Berardi F; Perrone R
Expert Opin Ther Pat; 2010 Jun; 20(6):739-54. PubMed ID: 20476847
[TBL] [Abstract][Full Text] [Related]
12. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives.
Ivachtchenko AV; Ivanenkov YA
Expert Opin Ther Pat; 2012 Aug; 22(8):917-64. PubMed ID: 22816965
[TBL] [Abstract][Full Text] [Related]
13. Serotonin receptor ligands and the treatment of obesity.
Vickers SP; Dourish CT
Curr Opin Investig Drugs; 2004 Apr; 5(4):377-88. PubMed ID: 15134278
[TBL] [Abstract][Full Text] [Related]
14. Novel 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 agonists and antagonists.
Elokdah H; Li D; McFarlane G; Bernotas RC; Robichaud AJ; Magolda RL; Zhang GM; Smith D; Schechter LE
Bioorg Med Chem; 2007 Sep; 15(18):6208-26. PubMed ID: 17624788
[TBL] [Abstract][Full Text] [Related]
15. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling.
Hirst WD; Abrahamsen B; Blaney FE; Calver AR; Aloj L; Price GW; Medhurst AD
Mol Pharmacol; 2003 Dec; 64(6):1295-308. PubMed ID: 14645659
[TBL] [Abstract][Full Text] [Related]
16. Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists.
Liu KG; Robichaud AJ; Greenfield AA; Lo JR; Grosanu C; Mattes JF; Cai Y; Zhang GM; Zhang JY; Kowal DM; Smith DL; Di L; Kerns EH; Schechter LE; Comery TA
Bioorg Med Chem; 2011 Jan; 19(1):650-62. PubMed ID: 21093272
[TBL] [Abstract][Full Text] [Related]
17. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
Terry AV; Buccafusco JJ; Wilson C
Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
[TBL] [Abstract][Full Text] [Related]
18. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
Wacker DA; Miller KJ
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
[TBL] [Abstract][Full Text] [Related]
19. Serotonin receptors and site-selective agents.
Glennon RA
J Physiol Pharmacol; 1991 Mar; 42(1):49-60. PubMed ID: 1932772
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
Medina RA; Sallander J; Benhamú B; Porras E; Campillo M; Pardo L; López-Rodríguez ML
J Med Chem; 2009 Apr; 52(8):2384-92. PubMed ID: 19326916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
